Get the Stockscreener App
0.56
8.23%
0.0426
After Hours:
.54
-0.02
-3.57%
Century Therapeutics Inc stock is traded at $0.56, with a volume of 1.38M.
It is up +8.23% in the last 24 hours and up +12.00% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.5174
Open:
$0.5174
24h Volume:
1.38M
Relative Volume:
2.43
Market Cap:
$48.25M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2445
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+4.28%
1M Performance:
+12.00%
6M Performance:
-54.10%
1Y Performance:
-82.11%
1-Day Range:
$0.5144
$0.5657
1-Week Range:
$0.475
$0.5657
52-Week Range:
$0.3418
$3.47
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.56 | 46.27M | 2.24M | -136.67M | -102.08M | -2.29 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MyChesCo
Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World
Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus
Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates - sharewise
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Century Therapeutics Expands iPSC Cell Therapy to Europe as Q1 Revenue Surges to $109M - Stock Titan
Marshall Wace LLP Purchases New Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Buys 91,468 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
A closer look at Century Therapeutics Inc (IPSC)’s stock price trends - uspostnews.com
Geode Capital Management LLC Acquires 23,413 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Century Therapeutics (IPSC) Expected to Announce Earnings on Thursday - Defense World
An Analysis of Century Therapeutics Inc (IPSC)’s Potential Price Growth - knoxdaily.com
Renaissance Technologies LLC Boosts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Market Insight: Century Therapeutics Inc (IPSC)’s Notable Drop, Closing at 0.50 - DWinneX
Century Therapeutics to Present Preclinical Data at ASGCT 28th Annual Meeting on Novel iPSC-Derived Cell Therapies for Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting - GlobeNewswire
Century Therapeutics Reveals Groundbreaking Cancer-Fighting Cell Therapy Data at Major Scientific Conference - Stock Titan
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Is it possible to buy Century Therapeutics Inc(IPSC) shares at a good price now? - uspostnews.com
Century Therapeutics Inc (IPSC): A Sitting Duck With -825.93% Upside Potential - Stocksregister
H.C. Wainwright maintains Buy rating on Century Therapeutics stock - Investing.com
Century Therapeutics Inc (IPSC)’s financial ratios: A comprehensive overview - DWinneX
H.C. Wainwright maintains Buy rating on Century Therapeutics stock By Investing.com - Investing.com UK
Century Therapeutics Inc [IPSC] Stock sold by Insider Pfeiffenberger Brent for $1375.0 - knoxdaily.com
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
Century Therapeutics to Host Live Chat on Preclinical Cell Therapy Programs Targeting Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics to Host Live Fireside Chat Focused on - GlobeNewswire
Century Therapeutics Unveils Next-Gen Cell Therapy Pipeline for Cancer and Autoimmune | IPSC Stock News - Stock Titan
American Century Companies Inc. Buys Shares of 105,337 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
American Century Companies Inc. Invests $231,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Sei Investments Co. Purchases New Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by American Century Companies Inc. - Defense World
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
American Century Companies Inc. Boosts Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
American Century Companies Inc. Increases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
American Century Companies Inc. Acquires 4,547 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
American Century Companies Inc. Purchases 13,916 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Buys 24,090 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
HC Wainwright Issues Positive Forecast for IPSC Earnings - Defense World
American Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
American Century Companies Inc. Has $3.36 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
American Century Companies Inc. Buys 1,622 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):